Author:
Stapleton Stacie L.,Reid Joel M.,Thompson Patrick A.,Ames Matthew M.,McGovern Renee M.,McGuffey Leticia,Nuchtern Jed,Dauser Robert,Blaney Susan M.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference16 articles.
1. Adjei AA (2000) Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors. Ann Oncol 11:1335–1341
2. Blaney SM, Poplack DG (1996) Pharmacologic strategies for the treatment of meningeal malignancy. Invest New Drugs 14:69–85
3. Chaudhary AK, Schannen V, Knadler MP, Lantz R, Le Lacheur RM (1999) Analysis of LY231514 by LC/MS/MS. In: Proceedings of 47th ASMS conference on Mass Spectrometry Allied Topics
4. Dy GK, Suri A, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Atherton PJ, Hanson LJ, Burch PA, Rubin J, Erlichman C, Adjei AA (2005) A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors. Cancer Chemother Pharmacol 55:522–530
5. Kim JH, Lee KW, Jung Y, Kim TY, Ham HS, Jong HS, Jung KH, Im SA, Kim TY, Kim NK, Bang YJ (2005) Cytotoxic effects of pemetrexed in gastric cancer cells. Cancer Sci 96:365–371
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献